| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
None; it is a chemical reagent with no inherent pharmacological activity. It does not bind to receptors or enzymes in a biologically meaningful way, except as a substrate for peptidases that cleave the amide bond.
|
|---|---|
| ln Vitro |
As a substrate, L-leucinamide hydrochloride is hydrolyzed by leucine aminopeptidase to release L-leucine and ammonia. In vitro, it does not exhibit any cytotoxic, anti-inflammatory, or other pharmacological effects at typical concentrations used in peptide synthesis. It may be used in enzyme kinetics studies to determine Michaelis-Menten parameters of aminopeptidases.
|
| ln Vivo |
Not applicable; this compound is not administered in vivo for therapeutic purposes. If ingested, it would be metabolized to leucine, but no pharmacological action is expected. It is not used in animal models for disease treatment.
|
| Enzyme Assay |
For leucine aminopeptidase activity assay, the compound is dissolved in Tris-HCl buffer (pH 8.5) at 1-10 mM. Enzyme is added, and hydrolysis is monitored by measuring ammonia production using Nessler's reagent or by HPLC detection of leucine. Kinetic parameters (Km, Vmax) are calculated from Lineweaver-Burk plots. Standard chemical purity is assessed by HPLC and melting point determination.
|
| Cell Assay |
Not applicable; this compound is not used in cell culture experiments. However, it could be included in media as a source of leucine for metabolic studies, but its amide form is not preferred over free amino acid. Cytotoxicity testing is not relevant.
|
| Animal Protocol |
Not applicable; no animal studies are conducted with this compound as a test substance. It may be used as a precursor in the synthesis of peptide drugs that are then tested in vivo, but the compound itself is not directly administered.
|
| ADME/Pharmacokinetics |
If administered orally, L-leucinamide hydrochloride would likely be rapidly hydrolyzed by intestinal peptidases to L-leucine, which is absorbed and incorporated into protein metabolism. The amide form may improve stability during peptide synthesis but has no distinct pharmacokinetic profile of its own.
|
| Toxicity/Toxicokinetics |
Generally regarded as safe at low doses; it is a simple amino acid derivative. Acute toxicity is low; oral LD₅₀ in rats is expected to be >2000 mg/kg. Skin and eye irritation may occur with direct contact. No carcinogenic or mutagenic effects are known. Standard laboratory handling with gloves and goggles is sufficient.
|
| References |
[1]. Madan BR, et al. Effect of L-leucinamide hydrochloride on experimental inflammation. Res Commun Chem Pathol Pharmacol. 1987 Dec;58(3):393-6.
|
| Additional Infomation |
L-Leucinamide hydrochloride is a routine biochemical reagent. It is not a drug candidate but an important building block for pharmaceutical peptide synthesis. Its stability and solubility make it convenient for coupling reactions. It is also used as a chiral standard in capillary electrophoresis and as a precursor for preparing leucine-based coordination compounds. Available for research and manufacturing use only.
|
| Molecular Formula |
C6H15CLN2O
|
|---|---|
| Molecular Weight |
166.65
|
| Exact Mass |
166.087
|
| CAS # |
10466-61-2
|
| PubChem CID |
2733199
|
| Appearance |
White to off-white solid powder
|
| Density |
0.98g/cm3
|
| Boiling Point |
250.9ºC at 760mmHg
|
| Melting Point |
254-256ºC
|
| Flash Point |
105.6ºC
|
| Vapour Pressure |
0.0211mmHg at 25°C
|
| LogP |
2.047
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].O=C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])[H])N([H])[H]
|
| InChi Key |
VSPSRRBIXFUMOU-JEDNCBNOSA-N
|
| InChi Code |
InChI=1S/C6H14N2O.ClH/c1-4(2)3-5(7)6(8)9;/h4-5H,3,7H2,1-2H3,(H2,8,9);1H/t5-;/m0./s1
|
| Chemical Name |
(2S)-2-amino-4-methylpentanamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0006 mL | 30.0030 mL | 60.0060 mL | |
| 5 mM | 1.2001 mL | 6.0006 mL | 12.0012 mL | |
| 10 mM | 0.6001 mL | 3.0003 mL | 6.0006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
